BACKGROUND: Management of human immunodeficiency virus (HIV) infection with potent antiretroviral medication has transformed HIV into a chronic condition and has shifted much of the burden of disease to co-morbid conditions such as liver disease (LD). LD alone has been shown to have a significant effect on one's health-related quality of life (HRQOL). Clinical evidence suggests that the growing number of persons living with HIV+LD may have a poorer HRQOL than persons with HIV without LD. To date, the widely accepted instrument to assess HRQOL, Medical Outcomes Study-HIV Health Survey (MOS-HIV), has not been evaluated for reliability and validity in a population of HIV-infected persons with LD. METHODS: HRQOL was prospectively assessed using the MOS-HIV in a sample of 532 HIV-infected adults on antiretroviral therapy (n=305 HIV and n=227 HIV+LD). In addition, participants completed standardized questionnaires of sociodemographics and co-morbid conditions. RESULTS: The psychometric properties of the MOS-HIV were supported by testing reliability and construct, convergent, discriminative, and predictive validity. The MOS-HIV discriminated between those persons living with HIV with and without LD on the basis of the physical function subscale scores (p=0.018). CONCLUSION: This study found the MOS-HIV valid and reliable instrument in persons with HIV+LD.
BACKGROUND: Management of human immunodeficiency virus (HIV) infection with potent antiretroviral medication has transformed HIV into a chronic condition and has shifted much of the burden of disease to co-morbid conditions such as liver disease (LD). LD alone has been shown to have a significant effect on one's health-related quality of life (HRQOL). Clinical evidence suggests that the growing number of persons living with HIV+LD may have a poorer HRQOL than persons with HIV without LD. To date, the widely accepted instrument to assess HRQOL, Medical Outcomes Study-HIV Health Survey (MOS-HIV), has not been evaluated for reliability and validity in a population of HIV-infectedpersons with LD. METHODS: HRQOL was prospectively assessed using the MOS-HIV in a sample of 532 HIV-infected adults on antiretroviral therapy (n=305 HIV and n=227 HIV+LD). In addition, participants completed standardized questionnaires of sociodemographics and co-morbid conditions. RESULTS: The psychometric properties of the MOS-HIV were supported by testing reliability and construct, convergent, discriminative, and predictive validity. The MOS-HIV discriminated between those persons living with HIV with and without LD on the basis of the physical function subscale scores (p=0.018). CONCLUSION: This study found the MOS-HIV valid and reliable instrument in persons with HIV+LD.
Authors: Wendy A Henderson; Jane M Fall-Dickson; Elizabeth A Schlenk; Kevin H Kim; Judith T Matthews; Judith A Erlen Journal: J Assoc Nurses AIDS Care Date: 2008 Sep-Oct Impact factor: 1.354
Authors: Colette Smit; Charlotte van den Berg; Ronald Geskus; Ben Berkhout; Roel Coutinho; Maria Prins Journal: J Acquir Immune Defic Syndr Date: 2008-02-01 Impact factor: 3.731
Authors: Katherine B Curtin; Yao I Cheng; Jichuan Wang; Rachel K Scott; Leah Squires; Debra A Benator; Maureen E Lyon Journal: Qual Life Res Date: 2018-09-15 Impact factor: 4.147
Authors: Rowan Saloner; Laura M Campbell; Vanessa Serrano; Jessica L Montoya; Elizabeth Pasipanodya; Emily W Paolillo; Donald Franklin; Ronald J Ellis; Scott L Letendre; Ann C Collier; David B Clifford; Benjamin B Gelman; Christina M Marra; J Allen McCutchan; Susan Morgello; Ned Sacktor; Dilip V Jeste; Igor Grant; Robert K Heaton; David J Moore Journal: J Int Neuropsychol Soc Date: 2019-03-20 Impact factor: 2.892
Authors: Maurice Michel; Alisha Wahl; Malena Anders; Saleh A Alqahtani; Wolfgang M Kremer; Peter R Galle; Christian Labenz; Daniel Grimm; Martin Sprinzl; Jörn M Schattenberg Journal: Qual Life Res Date: 2022-08-22 Impact factor: 3.440
Authors: Adaora A Adimora; Elizabeth Topper Golub; Seble G Kassaye; Aadia Rana; Daniel Westreich; Anandi N Sheth; Jennifer Webster Cyriaque; Carrigan Parish; Deborah Konkle-Parker; Deborah L Jones; Mirjam-Colette Kempf; Igho Ofotokun; Ruth M Kanthula; Jessica Donohue; Patricia Raccamarich; Tina Tisdale; Catalina Ramirez; Lari Warren-Jeanpiere; Phyllis C Tien; Maria L Alcaide Journal: JMIR Res Protoc Date: 2021-12-20